Roth Capital Estimates Clene’s Q1 Earnings (NASDAQ:CLNN)

Clene Inc. (NASDAQ:CLNN) – Roth Capital issued their Q1 2025 earnings estimates for Clene in a note issued to investors on Wednesday, November 13th. Roth Capital analyst J. Aschoff anticipates that the company will post earnings of ($0.86) per share for the quarter. The consensus estimate for Clene’s current full-year earnings is ($5.26) per share. Roth Capital also issued estimates for Clene’s Q2 2025 earnings at ($0.86) EPS, Q3 2025 earnings at ($0.85) EPS and Q4 2025 earnings at ($0.75) EPS.

A number of other analysts have also recently weighed in on CLNN. HC Wainwright reiterated a “buy” rating and issued a $31.00 price target on shares of Clene in a research report on Thursday. Canaccord Genuity Group dropped their target price on shares of Clene from $86.00 to $83.00 and set a “buy” rating for the company in a research report on Thursday. Finally, EF Hutton Acquisition Co. I upgraded shares of Clene to a “strong-buy” rating in a research report on Tuesday, September 10th.

Clene Trading Down 3.4 %

Shares of CLNN opened at $4.53 on Friday. The company has a current ratio of 0.99, a quick ratio of 0.99 and a debt-to-equity ratio of 1.66. The stock has a market cap of $31.06 million, a PE ratio of -0.86 and a beta of 0.42. Clene has a 1 year low of $3.82 and a 1 year high of $12.00. The stock has a 50 day simple moving average of $5.43 and a 200-day simple moving average of $6.01.

Hedge Funds Weigh In On Clene

A hedge fund recently bought a new stake in Clene stock. Castleview Partners LLC bought a new stake in Clene Inc. (NASDAQ:CLNN) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 12,783 shares of the company’s stock, valued at approximately $59,000. Castleview Partners LLC owned about 0.19% of Clene at the end of the most recent quarter. Institutional investors and hedge funds own 23.28% of the company’s stock.

Insider Activity

In related news, insider Mark Mortenson purchased 20,512 shares of the stock in a transaction that occurred on Monday, September 30th. The stock was acquired at an average price of $4.75 per share, with a total value of $97,432.00. Following the completion of the acquisition, the insider now directly owns 28,949 shares in the company, valued at approximately $137,507.75. This trade represents a 243.12 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director David J. Matlin acquired 92,307 shares of Clene stock in a transaction on Monday, September 30th. The shares were purchased at an average cost of $4.75 per share, for a total transaction of $438,458.25. Following the acquisition, the director now owns 444,491 shares in the company, valued at approximately $2,111,332.25. This represents a 26.21 % increase in their position. The disclosure for this purchase can be found here. 25.10% of the stock is currently owned by corporate insiders.

About Clene

Clene Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.